Cargando…

Ailanthone: a new potential drug for castration-resistant prostate cancer

Detalles Bibliográficos
Autores principales:	Peng, Shihong, Yi, Zhengfang, Liu, Mingyao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336637/ https://www.ncbi.nlm.nih.gov/pubmed/28257652 http://dx.doi.org/10.1186/s40880-017-0194-7

Ejemplares similares

Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
por: He, Yundong, et al.
Publicado: (2016)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
por: Cong, Xiaonan, et al.
Publicado: (2021)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
por: Wolff, Johannes M., et al.
Publicado: (2012)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Ailanthone: A novel potential drug for treating human cancer
por: Ding, Haixiang, et al.
Publicado: (2020)

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer
por: Hu, Meichun, et al.
Publicado: (2015)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Synthesis and biological evaluation of 3-nitro-4-chromanone derivatives as potential antiproliferative agents for castration-resistant prostate cancer
por: Chen, Huiqing, et al.
Publicado: (2019)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Highlight: Virtual Issue on Host–Pathogen Interactions and Antimicrobial Drug Resistance
por: McGrath, Casey
Publicado: (2022)

GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer
por: Wan, Lilin, et al.
Publicado: (2023)

Physiological and Transcriptomic Analysis of Arabidopsis thaliana Responses to Ailanthone, a Potential Bio-Herbicide
por: Hopson, Chantz Allen, et al.
Publicado: (2022)

New ideas in preventing castration-resistant prostate cancer
por: Tsai, Yuan-Chin, et al.
Publicado: (2017)

A new roadmap for the breeding of disease-resistant and high-yield crops
por: Wang, Yiming, et al.
Publicado: (2021)

Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012)

SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis
por: Xu, Shujing, et al.
Publicado: (2022)

ecDNA within tumors: a new mechanism that drives tumor heterogeneity and drug resistance
por: Zeng, Xixi, et al.
Publicado: (2020)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

New Therapeutics to Treat Castrate-Resistant Prostate Cancer
por: Acar, Ömer, et al.
Publicado: (2013)

New immunotherapeutic paradigms for castration-resistant prostate cancer
por: Galluzzi, Lorenzo
Publicado: (2013)

Definition of Castrate Resistant Prostate Cancer: New Insights
por: Morote, Juan, et al.
Publicado: (2022)

Immune receptor mimicking hormone receptors: a new guarding strategy
por: Liu, Xueru, et al.
Publicado: (2023)

Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
por: Kim, In-Wha, et al.
Publicado: (2019)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
por: Dragomir, Alice, et al.
Publicado: (2014)

The road to drug resistance in Mycobacterium tuberculosis
por: Koch, Anastasia, et al.
Publicado: (2014)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1k2rv998n1e8daaq8v2sdge0i9